retatrutide safety clinical trials This weight-loss drug hasn't been approved by the FDA. Doctors are prescribing it anyway Triple hormone receptor agonist retatrutide

Participants were White, Black, Caucasian, or of mixed race (Korean/White)

This information may help provide context for provider conversations about which formulation and dose strategy could align with an individual's genetic profile, though genetic variants do not predict exact medication response

The long-term effects of drugs that target systemic inflammation and metabolic pathways on autoimmune skin diseases needs further investigation

10.1038/srep10211 142 TurtonM

same time every day, especially after meals

Rare But Serious Risks Pancreatitis Gallbladder issues Kidney problems Talk to your doctor about these risks, especially if you have a history of these conditions